Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spleen Aminopeptide Oral Solution plus hyperthermia for plantar warts and condyloma acuminatum
ChiCTR2200056764Phase 4Completed
- Sponsor
- First Hospital of China Medical University
- Start
- Dec 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of spleen polypeptide in plantar wart and anogenital warts (2 arms), sponsored by First Hospital of China Medical University. Primary endpoints: Clearance rate of non-target warts at 6 months after treatment and Recovery duration. Started Dec 2021; status: completed.
02
Drugs
spleen polypeptide
03
Conditions
plantar wartanogenital warts
Beyond the preview
Go deeper on ChiCTR2200056764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056764.